Biohaven Enrolls First Patient in BHV-1300 Phase 3 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Biohaven announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves' disease. BHV-1300 is the first MoDE extracellular protein degrader, a novel small molecule IgG1, 2 and 4 degrader that harnesses the body's own clearance machinery to eliminate the IgG1 TSHR autoantibody driving Graves' disease. In over 70 years, no new therapy has been approved for Graves' disease. BHV-1300 is designed to change the treatment landscape for this autoimmune disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BHVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BHVN
Wall Street analysts forecast BHVN stock price to rise
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 14.880
Low
11.00
Averages
18.00
High
30.00
Current: 14.880
Low
11.00
Averages
18.00
High
30.00
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; Molecular Degrader of Extracellular Proteins (MoDE) and Targeted Removal of Aberrant Protein (TRAP) extracellular protein degradation for immunological diseases; and myostatin-activin pathway targeting agent for neuromuscular and metabolic diseases, including obesity. Its pipeline includes TYK2/JAK1 Inhibitor (brain-penetrant), IgG Degrader, Gd-IgA1 TRAP Degrader, Taldefgrobep Alfa, Kv7 Activator, TRPM3 Antagonist FGFR3 ADC, CD30 ADC, Trop2 ADC +/- PD1, and others. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biohaven Completes Enrollment in RISE3 Study for Opakalim
- Enrollment Completion: Biohaven announced the completion of enrollment in its pivotal RISE3 study evaluating opakalim for refractory focal epilepsy, with top-line results expected in the second half of 2026, marking a significant advancement in epilepsy treatment.
- Efficacy Data Presentation: In the ongoing open-label extension study, 54% of participants on opakalim 75 mg once daily achieved a ≥50% reduction in seizure frequency compared to baseline, demonstrating its potential efficacy and favorable tolerability, which may provide new treatment options for patients.
- Positive Patient Experience: The RISE3 study reported a high double-blind completion rate of approximately 95%, with around 95% of participants opting to roll over into the open-label extension study, reflecting favorable patient experiences and positive feedback on opakalim's profile, enhancing future market prospects.
- Innovative Drug Development: Opakalim, as a selective Kv7.2/7.3 channel activator, exhibits lower central nervous system side effects, potentially offering a superior treatment option for refractory epilepsy patients, further solidifying Biohaven's innovative position in the biopharmaceutical sector.
See More
Biohaven Completes Enrollment in RISE3 Study for Opakalim
- Enrollment Completion: Biohaven announced the completion of enrollment in the RISE3 study, which evaluates its selective Kv7.2/7.3 channel activator opakalim for refractory focal epilepsy, with top-line results expected in H2 2026, marking the approach of a new treatment option.
- Patient Participation Rates: Approximately 95% of participants completed the double-blind treatment period in the RISE3 study, and around 95% rolled over into the optional open-label extension study, indicating a favorable experience with opakalim and strong patient engagement in the trial.
- Efficacy Data Support: A recent analysis from the ongoing OLE study showed that 54% of participants on opakalim 75 mg achieved a ≥50% reduction in seizure frequency, with significantly lower rates of nervous system adverse events compared to other antiseizure medications, highlighting its potential superiority.
- Strategic Implications: Biohaven's Medical Director noted that completing enrollment in RISE3 is a significant milestone for the opakalim development program, signaling the company's innovative efforts in epilepsy treatment aimed at providing patients with more effective options that do not compromise their quality of life.
See More
BofA Downgrades Biohaven Rating and Price Target
- Rating Downgrade Impact: Bank of America downgraded Biohaven from ‘Neutral’ to ‘Underperform’ and cut the price target from $12 to $11, indicating a potential downside of about 26%, reflecting a bearish view on the risk-reward ahead of the upcoming Phase 3 data for its kv7 drug candidate.
- Surge in Short Interest: Following the downgrade, short interest in Biohaven surged to a record high of 16.70%, a significant increase from the lowest level of 3.50% in December 2022, indicating growing market concerns regarding the company's future performance.
- Clinical Trial Progress: Biohaven announced the enrollment of the first patient in a Phase 3 trial for BHV-1300 targeting Graves' disease, marking the first new therapy for the condition in over 70 years, showcasing the company's innovative potential in the treatment landscape.
- Polarized Market Sentiment: Despite a 475% surge in retail message volumes over the past 24 hours, market sentiment has polarized due to the BofA downgrade, with investors expressing concerns over the company's cash burn and clinical progress amidst the mixed reactions.
See More
U.S. Stocks Close Higher, Led by Technology Gains
- Tech Stock Surge: On Monday, the S&P 500 rose by 1.18%, the Dow Jones increased by 0.59%, and the Nasdaq 100 jumped by 2.25%, indicating a strong rebound in technology stocks that boosted overall market performance and reflected growing investor confidence in the tech sector.
- Geopolitical Easing: The U.S. and Iran agreed to halt hostilities in the Strait of Hormuz ahead of peace talks, providing market support and alleviating investor concerns over geopolitical risks, which contributed to the stock market's upward movement.
- Oil Price Volatility: Although WTI crude oil prices surged over 2% due to escalating tensions, they retreated after the U.S. and Iran reached a temporary ceasefire, highlighting the market's sensitivity to oil price fluctuations and expectations for future economic growth.
- Economic Confidence Indicator Rise: The Eurozone's June economic confidence indicator rose to 95.0, surpassing expectations of 94.3, suggesting signs of economic recovery that may further enhance investor optimism and promote capital inflows into the market.
See More
US Stocks Rise, Led by Technology Sector Gains
- Tech Sector Surge: Major US stock indices rose today, with the Nasdaq 100 up 1.08%, primarily driven by gains in the Magnificent Seven tech stocks, indicating strong market confidence in the technology sector that may attract further investor interest.
- Geopolitical Easing: The US and Iran reached a temporary ceasefire agreement, easing tensions in the Strait of Hormuz, which positively impacted the market as crude oil prices rose over 1%, while reducing demand for safe-haven assets, thus boosting stock prices.
- Economic Confidence Rise: The Eurozone's June economic confidence indicator increased to 95.0, surpassing expectations of 94.3, signaling signs of economic recovery that could influence future monetary policy decisions and further support market sentiment.
- Mixed Stock Performance: Stocks like Amazon and Tesla rose over 4%, while Apple saw a decline of 0.56%, reflecting varied market reactions to different companies, prompting investors to pay attention to individual stock fundamentals.
See More
US Stocks Rise, Led by Technology Sector Gains
- Tech Sector Surge: Major US stock indices rose today, with the Dow Jones Industrial Average up 0.64% and the Nasdaq 100 up 0.67%, reflecting a strong rebound in technology stocks, particularly the Magnificent Seven, which significantly boosted overall market performance.
- Geopolitical Easing: The US and Iran reached a temporary ceasefire agreement, agreeing to halt attacks in the Strait of Hormuz, paving the way for upcoming peace talks in Doha, which has lifted market sentiment and reduced investor demand for safe-haven assets.
- Oil Price Fluctuations: Although WTI crude oil prices rose over 1% due to escalating geopolitical tensions, the market's expectations for oil prices have moderated following the ceasefire agreement, indicating a focus on future supply-demand balance.
- Economic Confidence Indicator Rise: The Eurozone's June economic confidence indicator increased to 95.0, surpassing expectations of 94.3, reflecting optimistic market sentiment regarding economic recovery, which may further bolster investor confidence in the stock market.
See More
Biohaven Completes Enrollment in RISE3 Study for Opakalim
- Enrollment Completion: Biohaven announced the completion of enrollment in its pivotal RISE3 study evaluating opakalim for refractory focal epilepsy, with top-line results expected in the second half of 2026, marking a significant advancement in epilepsy treatment.
- Efficacy Data Presentation: In the ongoing open-label extension study, 54% of participants on opakalim 75 mg once daily achieved a ≥50% reduction in seizure frequency compared to baseline, demonstrating its potential efficacy and favorable tolerability, which may provide new treatment options for patients.
- Positive Patient Experience: The RISE3 study reported a high double-blind completion rate of approximately 95%, with around 95% of participants opting to roll over into the open-label extension study, reflecting favorable patient experiences and positive feedback on opakalim's profile, enhancing future market prospects.
- Innovative Drug Development: Opakalim, as a selective Kv7.2/7.3 channel activator, exhibits lower central nervous system side effects, potentially offering a superior treatment option for refractory epilepsy patients, further solidifying Biohaven's innovative position in the biopharmaceutical sector.
See More
Biohaven Completes Enrollment in RISE3 Study for Opakalim
- Enrollment Completion: Biohaven announced the completion of enrollment in the RISE3 study, which evaluates its selective Kv7.2/7.3 channel activator opakalim for refractory focal epilepsy, with top-line results expected in H2 2026, marking the approach of a new treatment option.
- Patient Participation Rates: Approximately 95% of participants completed the double-blind treatment period in the RISE3 study, and around 95% rolled over into the optional open-label extension study, indicating a favorable experience with opakalim and strong patient engagement in the trial.
- Efficacy Data Support: A recent analysis from the ongoing OLE study showed that 54% of participants on opakalim 75 mg achieved a ≥50% reduction in seizure frequency, with significantly lower rates of nervous system adverse events compared to other antiseizure medications, highlighting its potential superiority.
- Strategic Implications: Biohaven's Medical Director noted that completing enrollment in RISE3 is a significant milestone for the opakalim development program, signaling the company's innovative efforts in epilepsy treatment aimed at providing patients with more effective options that do not compromise their quality of life.
See More
BofA Downgrades Biohaven Rating and Price Target
- Rating Downgrade Impact: Bank of America downgraded Biohaven from ‘Neutral’ to ‘Underperform’ and cut the price target from $12 to $11, indicating a potential downside of about 26%, reflecting a bearish view on the risk-reward ahead of the upcoming Phase 3 data for its kv7 drug candidate.
- Surge in Short Interest: Following the downgrade, short interest in Biohaven surged to a record high of 16.70%, a significant increase from the lowest level of 3.50% in December 2022, indicating growing market concerns regarding the company's future performance.
- Clinical Trial Progress: Biohaven announced the enrollment of the first patient in a Phase 3 trial for BHV-1300 targeting Graves' disease, marking the first new therapy for the condition in over 70 years, showcasing the company's innovative potential in the treatment landscape.
- Polarized Market Sentiment: Despite a 475% surge in retail message volumes over the past 24 hours, market sentiment has polarized due to the BofA downgrade, with investors expressing concerns over the company's cash burn and clinical progress amidst the mixed reactions.
See More
U.S. Stocks Close Higher, Led by Technology Gains
- Tech Stock Surge: On Monday, the S&P 500 rose by 1.18%, the Dow Jones increased by 0.59%, and the Nasdaq 100 jumped by 2.25%, indicating a strong rebound in technology stocks that boosted overall market performance and reflected growing investor confidence in the tech sector.
- Geopolitical Easing: The U.S. and Iran agreed to halt hostilities in the Strait of Hormuz ahead of peace talks, providing market support and alleviating investor concerns over geopolitical risks, which contributed to the stock market's upward movement.
- Oil Price Volatility: Although WTI crude oil prices surged over 2% due to escalating tensions, they retreated after the U.S. and Iran reached a temporary ceasefire, highlighting the market's sensitivity to oil price fluctuations and expectations for future economic growth.
- Economic Confidence Indicator Rise: The Eurozone's June economic confidence indicator rose to 95.0, surpassing expectations of 94.3, suggesting signs of economic recovery that may further enhance investor optimism and promote capital inflows into the market.
See More
US Stocks Rise, Led by Technology Sector Gains
- Tech Sector Surge: Major US stock indices rose today, with the Nasdaq 100 up 1.08%, primarily driven by gains in the Magnificent Seven tech stocks, indicating strong market confidence in the technology sector that may attract further investor interest.
- Geopolitical Easing: The US and Iran reached a temporary ceasefire agreement, easing tensions in the Strait of Hormuz, which positively impacted the market as crude oil prices rose over 1%, while reducing demand for safe-haven assets, thus boosting stock prices.
- Economic Confidence Rise: The Eurozone's June economic confidence indicator increased to 95.0, surpassing expectations of 94.3, signaling signs of economic recovery that could influence future monetary policy decisions and further support market sentiment.
- Mixed Stock Performance: Stocks like Amazon and Tesla rose over 4%, while Apple saw a decline of 0.56%, reflecting varied market reactions to different companies, prompting investors to pay attention to individual stock fundamentals.
See More
US Stocks Rise, Led by Technology Sector Gains
- Tech Sector Surge: Major US stock indices rose today, with the Dow Jones Industrial Average up 0.64% and the Nasdaq 100 up 0.67%, reflecting a strong rebound in technology stocks, particularly the Magnificent Seven, which significantly boosted overall market performance.
- Geopolitical Easing: The US and Iran reached a temporary ceasefire agreement, agreeing to halt attacks in the Strait of Hormuz, paving the way for upcoming peace talks in Doha, which has lifted market sentiment and reduced investor demand for safe-haven assets.
- Oil Price Fluctuations: Although WTI crude oil prices rose over 1% due to escalating geopolitical tensions, the market's expectations for oil prices have moderated following the ceasefire agreement, indicating a focus on future supply-demand balance.
- Economic Confidence Indicator Rise: The Eurozone's June economic confidence indicator increased to 95.0, surpassing expectations of 94.3, reflecting optimistic market sentiment regarding economic recovery, which may further bolster investor confidence in the stock market.
See More
